Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring

Biomedical Chromatography

Volumn 26, Issue 12, 2012, Pages 1519-1528

  Shibata, Mai ^a   Hashi, Sachiyo ^b   Nakanishi, Haruka ^a   Masuda, Satohiro ^b   Katsura, Toshiya ^b   Yano, Ikuko ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antiepileptics; Human plasma; Therapeutic drug monitoring; UPLC MS MS

Indexed keywords

AMIDES; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATIENT MONITORING;

ACQUITY; ANTIEPILEPTICS; ANTIEPILEPTICS DRUGS; CARBAMAZEPINE; HUMAN PLASMAS; MOBILE PHASIS; PHENYTOIN; THERAPEUTIC DRUG MONITORING; THERAPEUTIC MONITORING; UPLC-MS/MS;

METHANOL;

AMMONIUM ACETATE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FORMIC ACID; GABAPENTIN; LAMOTRIGINE; METHANOL; NITRAZEPAM; NORCLOBAZAM; NORDAZEPAM; NORMESUXIMIDE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; WATER; ZONISAMIDE;

ACCURACY; ANALYTICAL EQUIPMENT; ARTICLE; CALIBRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; DRUG MONITORING; DRUG STABILITY; EVAPORATION; FLOW RATE; IMMUNOASSAY; INTERMETHOD COMPARISON; PRECIPITATION; QUALITY CONTROL; SUPERNATANT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION STUDY;

EID: 84867740189     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2726     Document Type: Article

References (20)

1. Bansal S and DeStefano A. Key elements of bioanalytical method validation for small molecules. The AAPS Journal 2007; 30: E109-114.
2. Bhatt M, Shah S and Shivprakash. Rapid ultraperformance liquid chromatography-tandem mass spectrometry method for quantification of oxcarbazepine and its metabolite in human plasma. Biomedical Chromatography 2011; 25: 751-759.
3. Bland JM and Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
4. Breton H, Cociglio M, Bressolle F, Peyriere H, Blayac JP and Hillaire-Buys D. Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. Journal of Chromatography B 2005; 828: 80-90.
5. FDA. Guidance for Industry. Bioanalytical Method Validation. US Department of Health and Human Services, FDA, CDER and CVM: Washington, DC, 2001.
6. Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T and Patsalos PN. Therapeutic drug monitoring of the newer antiepileptic drugs. Therapeutic Drug Monitoring 2003; 25: 347-363.
7. Juenke JM, Brown PI, Johnson-Davis KL and McMillin GA. Simultaneous quantification of levetiracetam and gabapentin in plasma by ultra-pressure liquid chromatography coupled with tandem mass spectrometry detection. Therapeutic Drug Monitoring 2011; 33: 209-213.
8. Juergens U. Simultaneous determination of zonisamide and nine other antiepileptic drugs and metabolites in serum. A comparison of microbore and conventional high-performance liquid chromatography. Journal of Chromatography 1987; 385: 233-240.
9. Kabra PM, Stafford BE and Marton LJ. Simultaneous measurement of phenobarbital, phenytoin, primidone, ethosuximide, and carbamazepine in serum by high-pressure liquid chromatography. Clinical Chemistry 1977; 23: 1284-1288.
10. Kim KB, Seo KA, Kim SE, Bae SK, Kim DH and Shin JG. Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2011; 56: 771-777.
11. Landmark CJ and Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Review of Neurotherapeutics 2010; 10: 119-140.
12. McMillin GA, Juenke JM, Tso G and Dasgupta A. Estimation of carbamazepine and carbamazepine-10, 11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays. American Journal of Clinical Pathology 2010; 133: 728-736.
13. Mendu DR and Soldin SJ. Simultaneous determination of levetiracetam and its acid metabolite (ucb L057) in serum/plasma by liquid chromatography tandem mass spectrometry. Clinical Biochemistry 2010; 43: 485-489.
14. Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM and Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clinical Chemistry and Laboratory Medicine 2004; 42: 1228-1255.
15. Parant F, Bossu H, Gagnieu MC, Lardet G and Moulsma M. Cross-reactivity assessment of carbamazepine-10, 11-epoxide, oxcarbazepine, and 10-hydroxy-carbazepine in two automated carbamazepine immunoassays: PETINIA and EMIT 2000. Therapeutic Drug Monitoring 2003; 25: 41-45.
16. Patsalos PN, Froscher W, Pisani F and van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-385.
17. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T and Perucca E. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
18. Subramanian M, Birnbaum AK and Remmel RP. High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. Therapeutic Drug Monitoring 2008; 30: 347-356.
19. Szabo GK and Browne TR. Improved isocratic liquid chromatographic simultaneous measurement of phenytoin, phenobarbital, primidone, carbamazepine, ethosuximide, and N-desmethylmethsuximide in serum. Clinical Chemistry 1982; 28: 100-104.
20. Tomson T and Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. European Journal of Clinical Pharmacology 2000; 55: 697-705.